A previous study reported that BRAF V600E mutation is associated with aggressive disease and must be investigated in patients with small papillary thyroid carcinoma (< 1.5 cm) or papillary microcarcinoma (< 1 cm) to help identify high‐risk groups and initiate ideal treatment [32]. This evidence concerns the gene BRAF and thyroid gland papillary carcinoma.